Literature DB >> 23298273

Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.

X Ge1, C-R Li, J Yang, G-B Wang.   

Abstract

This study is designed to investigate the changes of NKG2D expression on CD8(+) T cells and CD3(-) CD56(+) NK cells in Kawasaki disease (KD). NKG2D/NKG2A expression on CD3(-) CD56(+) NK cells and CD8(+) T lymphocytes, and NKG2D ligands such as major histocompatibility complex I chain-related molecules A(MICA) and UL-16-binding proteins (ULBP-1) expression on CD14(+) mononuclear cells (MC) were analysed by flow cytometry in patients with KD. Real-time polymerase chain reaction (PCR) was used to evaluate the mRNA levels of interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)-α in CD14(+) cells. Plasma cytokine [IL-7, IL-12, IL-15, interferon (IFN)-γ and transforming growth factor (TGF)-β] concentrations were measured by ELISA. The levels of NKG2D on NK cells and CD8(+) T cells expression in acute phase of KD were significantly lower than those in normal controls (P < 0.05), and the levels of NKG2D expression in the patients with coronary artery lesion (KD-CAL(+) ) were lower than those in patients with KD-CAL(-) . There was an upregulated tendency after treatment with IVIG. We found higher expression levels of proinflammatory cytokines from MC, such as IL-1β, IL-6 and TNF-α in patients with KD compared with the healthy controls (P < 0.05). The concentrations of IL-7 and IL-15 were significantly decreased in acute phase of KD (P < 0.05) and to some extent elevated after therapy with IVIG (P < 0.05), while antagonistic cytokines like IFN-γ were increased in acute phase of KD (P < 0.05) and reduced after therapy with IVIG (P < 0.05). These results suggest that aberrantly decreased levels of NKG2D expression on NK cells and CD8(+) T cells might be one of the factors led to disturbed immunological function in patients with KD. Cytokines milieu could be important factors causing reduced expression of NKG2D.
© 2013 The Authors. Scandinavian Journal of Immunology © 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23298273     DOI: 10.1111/sji.12022

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  13 in total

Review 1.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

Review 2.  The Immunogenetics of Vasculitis.

Authors:  Fotini B Karassa; Eleftherios Pelechas; Georgios Zouzos
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.

Authors:  Clara Di Vito; Francesca Calcaterra; Nicolò Coianiz; Sara Terzoli; Antonio Voza; Joanna Mikulak; Silvia Della Bella; Domenico Mavilio
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 4.  Natural killer cell education in human health and disease.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Curr Opin Immunol       Date:  2018-02-03       Impact factor: 7.486

Review 5.  CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?

Authors:  Rosanne D Reitsema; Annemieke M H Boots; Kornelis S M van der Geest; Maria Sandovici; Peter Heeringa; Elisabeth Brouwer
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

Review 6.  The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.

Authors:  Mahda Delshad; Naeimeh Tavakolinia; Atieh Pourbagheri-Sigaroodi; Ava Safaroghli-Azar; Nader Bagheri; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2021-03-18       Impact factor: 5.714

7.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 8.  Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation.

Authors:  Michael Henrickson; Heng Wang
Journal:  Clin Rheumatol       Date:  2017-03-13       Impact factor: 2.980

Review 9.  More than Decoration: Roles for Natural Killer Group 2 Member D Ligand Expression by Immune Cells.

Authors:  Andrew P Trembath; Mary A Markiewicz
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

10.  Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH?

Authors:  Mohammed S Osman; Charmaine van Eeden; Jan Willem Cohen Tervaert
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.